Published: Mar 30, 2009
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced today that it has initiated a Phase 2a clinical trial of its novel anti-von Willebrand Factor (VWF) aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a potential first-in-class antiplatelet agent in patients with carotid artery disease undergoing a surgical procedure known as carotid endarterectomy, or CEA.